- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07266441
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (TRIlogy-3)
A Phase 2, Open-label Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Beijing, China, 100006
- Peking Union Medical College Hospital
-
Chaoyang District, China, 100020
- Beijing Chaoyang Hospital
-
Guangzhou, China, 510700
- Sun Yat Sen University Cancer Center
-
Shanghai, China, 200434
- Shanghai Fourth People s Hospital
-
-
-
-
-
Afula, Israel, 1834111
- Ha'Emek Medical Center
-
Ashdod, Israel, 7747629
- Samson Assuta Ashdod University Hospital
-
Hadera, Israel, 3820302
- Hillel Yaffe Medical Center
-
Jerusalem, Israel, 9112000
- Hadassah Medical Center
-
Petah Tikva, Israel, 4941492
- Rabin Medical Center
-
Tel Aviv, Israel, 6423906
- Tel Aviv Sourasky Medical Center
-
-
-
-
-
Bergamo, Italy, 24127
- ASST Papa Giovanni XXIII Bergamo
-
Bologna, Italy, 40138
- Policlinico Sant'Orsola Malpighi
-
Cuneo, Italy, 12100
- Azienda Ospedaliera S Croce e Carle Cuneo
-
Florence, Italy, 50134
- Azienda Ospedaliero Universitaria Careggi
-
Palermo, Italy, 90127
- Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
-
Pavia, Italy, 27100
- IRCCS Policlinico San Matteo, Università degli studi di Pavi
-
Pescara, Italy, 65124
- Presidio Ospedaliero Pescara
-
Roma, Italy, 00161
- AOU Policlinico Umberto I
-
Verona, Italy, 37134
- Centro Ricerche Cliniche di Verona S r l
-
-
-
-
-
Gunma, Japan, 377-0280
- National Hospital Organization Shibukawa Medical Center
-
Okayama, Japan, 701-1192
- National Hospital Organization Okayama Medical Center
-
-
-
-
-
Brzozów, Poland, 36 200
- Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza
-
Kielce, Poland, 25 734
- Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach
-
Krakow, Poland, 30 688
- Samodzielny Publiczny Zaklad Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
-
Lodz, Poland, 93 513
- Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im M Kopernika w Lodzi
-
Lublin, Poland, 20 081
- Uniwersytecki Szpital Kliniczny Nr 1 w Lublinie
-
Poznan, Poland, 60-569
- Uniwersytecki Szpital Kliniczny w Poznaniu
-
Torun, Poland, 87 100
- Wojewodzki Szpital Zespolony im L Rydygiera w Toruniu
-
Wroclaw, Poland, 50 367
- Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu
-
-
-
-
-
Jeollanam-do, South Korea, 58128
- Chonnam National University Hwasun Hospital
-
Seoul, South Korea, 03080
- Seoul National University Hospital
-
Seoul, South Korea, 05505
- Asan Medical Center
-
Seoul, South Korea, 03722
- Severance Hospital Yonsei University Health System
-
Seoul, South Korea, 06351
- Samsung Medical Center
-
Seoul, South Korea, 06591
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Ankara, Turkey (Türkiye), 06680
- Liv Hospital Ankara
-
Ankara, Turkey (Türkiye), 06590
- Ankara University Medical Faculty
-
Antalya, Turkey (Türkiye), 07025
- Memorial Antalya Hospital
-
Istanbul, Turkey (Türkiye), 34214
- Medipol University Hospital
-
Istanbul, Turkey (Türkiye), 34381
- Istanbul Florance Nightingale Hospital
-
Sakarya, Turkey (Türkiye), 54050
- Sakarya Üniversitesi Tıp Fakültesi Hastanesi
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- O Neal Comprehensive Cancer Center at UAB
-
-
Arizona
-
Gilbert, Arizona, United States, 85234
- Banner MD Anderson Cancer Center
-
-
California
-
Duarte, California, United States, 91010
- City of Hope
-
Irvine, California, United States, 92618
- City of Hope Orange County Lennar Foundation Cancer Center
-
Los Alamitos, California, United States, 90720
- Cancer and Blood Specialty Clinic
-
San Francisco, California, United States, 94143
- University of California San Francisco
-
-
Colorado
-
Aurora, Colorado, United States, 80012
- Rocky Mountain Cancer Centers
-
Denver, Colorado, United States, 80218
- Colorado Blood Cancer Institute
-
-
Florida
-
Jacksonville, Florida, United States, 32256
- Cancer Specialists of North Florida
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
Atlanta, Georgia, United States, 30342
- Northside Hospital Cancer Institute
-
-
Illinois
-
O'Fallon, Illinois, United States, 62269
- Cancer Care Specialists of Central Illinois
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa
-
Waukee, Iowa, United States, 50263
- Mission Cancer Blood
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
-
New Jersey
-
New Brunswick, New Jersey, United States, 08901
- Rutgers Cancer Institute
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Levine Cancer Institute
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Cleveland Clinic Foundtation
-
-
Oregon
-
Eugene, Oregon, United States, 97401
- Oncology Associates of Oregon PC Willamette Valley Cancer Institute
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Tennessee Oncology, PLLC
-
Nashville, Tennessee, United States, 37203
- SCRI Oncology Partners
-
-
Texas
-
Austin, Texas, United States, 78705
- Texas Oncology
-
Houston, Texas, United States, 77030
- MD Anderson Cancer Center
-
Houston, Texas, United States, 77030
- Oncology Consultants Texas
-
Tyler, Texas, United States, 75702
- Texas Oncology - Northeast
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Virginia Cancer Specialists
-
Norfolk, Virginia, United States, 23502
- Virginia Oncology Associates
-
-
Washington
-
Tacoma, Washington, United States, 98405
- NorthWest Medical Specialties, PLLC
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion:
-
Documented diagnosis of multiple myeloma (MM) as defined by the criteria below:
- MM diagnosis according to the international myeloma working group (IMWG) diagnostic criteria
- Measurable disease at screening as assessed by central laboratory
-
Received at least 3 prior lines of antimyeloma therapy including a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-cluster of differentiation (CD) 38 monoclonal antibody (mAb)
-
Documented evidence of progressive disease(PD) or failure to achieve a response to the last line of therapy based on investigator's determination of response by the IMWG criteria
-
Have discontinued concurrent use of any other anticancer treatment (including nonpalliative radiotherapy) or investigational agent
-
Have an eastern cooperative oncology group (ECOG) performance status (PS) of 0 to 2 at screening and immediately before the start of study treatment administration
Exclusion:
- Suspected or known allergies, hypersensitivity, or intolerance to excipients of JNJ-79635322
- Had major surgery within 2 weeks before first dose or has planned major surgery during study treatment phase
- Known active or prior central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM
- Participant has leptomeningeal disease
- Participant has a prior or concurrent second malignancy the natural history or treatment of which could likely interfere with any study endpoints of safety or the efficacy of the study treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: JNJ-79635322
Participants will receive JNJ-79635322 as an injection under the skin. |
JNJ-79635322 will be administered as an injection under the skin. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall Response Rate (ORR)
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Very Good Partial Response (VGPR) or Better Rate
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Complete Response (CR) or Better Rate
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Duration of Response (DoR)
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Progression-Free Survival (PFS)
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Overall Survival (OS)
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Time To Next Line of Therapy (TTNT)
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Number of Participants With Treatment-Emergent Adverse Event (TEAE) by Severity
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Change from Baseline in Symptoms, Functioning, and Health-related Quality of Life (HRQoL) as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score
Time Frame: From Baseline up to 2 years and 9 months
|
From Baseline up to 2 years and 9 months
|
|
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by European Organization for Research and Treatment of Cancer Quality of life Questionnaire Core 30 (EORTC-QLQ-C30) Scale Score
Time Frame: From Baseline up to 2 years and 9 months
|
From Baseline up to 2 years and 9 months
|
|
Change from Baseline in Symptoms, Functioning, and HRQoL as Assessed by European Quality of Life 5-Dimensions 5-Level Version (EQ-5D-5L) Scale Score
Time Frame: From Baseline up to 2 years and 9 months
|
From Baseline up to 2 years and 9 months
|
|
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by MySIm-Q
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Time to Worsening in Symptoms, Functioning, and HRQoL as Assessed by EQ-5D-5L
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Percentage of Participants With Meaningful Improvement in Symptoms, Functioning, and HRQoL as Assessed by MySIm-Q
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Percentage of Participants With Meaningful Improvement in Symptoms, Functioning, and HRQoL as Assessed by EORTC-QLQ-C30
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Percentage of Participants With Meaningful Improvement in Symptoms, Functioning, and HRQoL as Assessed by EQ-5D-5L
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Serum Concentrations for JNJ-79635322
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Number of Participants With Anti JNJ-79635322 Antibodies
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
|
Number of Participants With JNJ-79635322 Neutralizing Antibodies (NAb)
Time Frame: Up to 2 years and 9 months
|
Up to 2 years and 9 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Vascular Diseases
- Cardiovascular Diseases
- Neoplasms
- Immune System Diseases
- Neoplasms by Histologic Type
- Hematologic Diseases
- Lymphoproliferative Disorders
- Immunoproliferative Disorders
- Neoplasms, Plasma Cell
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Hemorrhagic Disorders
- Hemic and Lymphatic Diseases
- Multiple Myeloma
Other Study ID Numbers
- 79635322MMY2001
- 79635322MMY2001 (Other Identifier: Janssen Research & Development, LLC)
- 2025-521976-80-00 (Registry Identifier: EUCT number)
- 2025 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.